Canadian Pharma Company HYTN Inks Deal To Supply Medical Marijuana To UK, Eyes Germany And Australia Expansion

Pharmaceutical company focused on cannabinoids and psilocybin products, HYTN Innovations Inc. (OTCPK:HYTNF), partnered with 4C LABS, an importer and distributor of cannabis-based pharmaceuticals in the United Kingdom. The British Columbia-based company said this collaboration will enable the manufacturing of cannabis products in bulk and final packaged forms for distribution in the UK and other global markets.

Under this partnership, HYTN will act as producer, packager and exporter of pharmaceutical quality cannabis products that 4C LABS can acquire and import and distribute into the UK. HYTN has a Health Canada’s Good Manufacturing Practice (GMP) license and a PIC/S certification from Australia’s Therapeutic Goods Administration (TGA) which allows for its products to meet the European and Australian standards.

“This partnership validates the ongoing regulatory work HYTN has been undertaking,” stated Elliot McKerr, chief executive officer of HYTN. “By integrating 4C Labs’ deep understanding of cannabis procurement and consumer demand with …

Full story available on Benzinga.com